Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s ...
A live link to the presentation will be located under “ Events ” in the Investors section of the Company’s website at www.actuatetherapeutics.com. A replay of the webcast will be available on ...
Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data evaluating DecisionDx-Melanoma’s i31-SLNB test ...
Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– BEDFORD, Mass. and ...
HITRUST r2 Certification demonstrates that HealthRecon Connect’s certified systems have met demanding regulatory compliance and industry-defined requirements and are appropriately managing risk. This ...
BillionToOne now expects full year 2026 total revenue of $430 million to $445 million, representing growth of 41% to 46% compared to full year 2025. This compares to the company’s previous guidance of ...
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced the company will participate at the following investor ...
The offering was structured as a straightforward common stock only investment with no warrant coverage and was led by healthcare-dedicated investors alongside existing shareholders. Konik Capital ...
NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued an inducement award to a new employee.
Wells Fargo Securities is acting as the underwriter for the Offering. The underwriter will offer the shares from time to time in one or more transactions on Nasdaq, in the over-the-counter market or ...
On September 2025, SCYNEXIS announced positive Phase 1 SAD/MAD results for the oral formulation of its second-generation fungerp, SCY-247, demonstrating good tolerability, favorable pharmacokinetics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results